Navigation Links
Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
Date:8/25/2011

with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy – practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.

This press release contains forward-looking statements about linagliptin tablets for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that linagliptin will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

P-LLY

TJ110702PR

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO)

(1)Trajenta™ (linagliptin) tablets. EMA Summary of Product Characteristics. 2011.

(
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
2. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
3. Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "Arthroscopy ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose ... size the world market for Arthroscopy Devices. ... trends impacting the market for these products. ...
(Date:5/21/2015)... NEW YORK , 21. Mai ... (NASDAQ: DPRX ), ein Unternehmen ... sich auf die Entwicklung und Vermarktung ... Forschungszusammenarbeit konzentriert, kündigte heute eine wissenschaftliche ... der Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 ...
(Date:5/21/2015)... , May 21, 2015 Research and Markets ... addition of the "Global Next Generation Sequencing ... The global next generation sequencing market to ... period 2014-2019 This report covers the ... global next generation sequencing market for the period ...
Breaking Medicine Technology:Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Global Next Generation Sequencing Market 2015-2019 2
... Researchers,testing a vaccine based on the live bacteria Listeria, ... safe. The Lovaxin C vaccine being,developed by Advaxis Inc. ... and head and neck cancers that result from the ... vaccine had been,treated in humans. "Our long held ...
... November 2 at the American Society of Nephrology ... ... Inc. (Nasdaq: EXEL ) announced that a recently completed phase 2,trial ... placebo in patients with proteinuria associated with diabetic,nephropathy. Exelixis is continuing to ...
Cached Medicine Technology:New Study Shows Listeria Vaccine for Cervical Cancer Found Safe 2Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 2Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 3Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 4
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 ... Sunset Plaza Dental announces that they are now ... restorative and other dental treatments. At consultations, patients ... them. Questions regarding what certain treatments can achieve ... be covered during this initial appointment. If treatments ...
(Date:5/22/2015)... Boca Raton, FL (PRWEB) May 22, 2015 ... organization which provides vascular, electrocardiogram (EKG), echocardiogram and ... of David Sempier, a highly respected All American National ... a multi-sport athlete, I find the high level of ... to both the athlete and their athletic trainers, this ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... In efforts to offer full and ... particular muscles stretches has been a large focus over ... now complete, Chunk Fitness envisions a mid-June launch of ... and released at a later point in time. The ... http://www.chunkfitness.com/stretches . , About the Company: Chunk Fitness was ...
(Date:5/21/2015)... York (PRWEB) May 21, 2015 World ... patented products, launches the Troll Motor Guide, a boat ... of boating. , "The recreational boating industry has reached ... Cooper, CEO and Creative Director of World Patent ... record numbers and predicts continued steady growth of seven ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... Bioinformatics Institute (VBI) Assistant Professor Biswarup Mukhopadhyay has ... type 2 diabetics in the// December 22, 2006, ... should in time help researchers to identify potential ... but not fully eliminate, the body's overproduction of ...
... in the list of ‘deadliest’ cancers, which is a wake ... disease in// the early stage. The Ontario government is investing ... cancer. This plan will adopt two crucial approaches, targeting men ... year screening program for men aged 50 to 74, promises ...
... for some years, that mother and baby exchange stem cells ... on for many// years, apparently tolerated by the new host. ... presence of such cells can be harmful to the recipient. ... in children with type 1 diabetes, an immune-mediated disorder, and ...
... Imagine having a decayed tooth repaired, painlessly, without drilling or ... ,Wishful thinking? Not if two studies being conducted at the ... ,In one study, funded by a $100,000 grant ... Studies are testing a nasal spray that numbs the upper ...
... have come out with findings from a study that ... like celexa in combating// depression. ,Dr. Fran?ois ... his colleagues published their findings in this week’s edition ... ,The drug celexa, which goes by the generic ...
... disease has been identified in HIV-positive patients. Investigators in ... at a specialist liver centre had nodular regenerative hyperplasia, ... ,The syndrome involves the build-up of pressure in ... liver and can cause bleeding into the stomach. Writing ...
Cached Medicine News:Health News:VBI Provides Potential Targets to Diabetes Therapeutics 2Health News:Stem Cells Passed From Mother to Child Live On and Make Insulin 2Health News:Dental Researchers Test No-Needle Anesthesia, No-Drilling Cavity Care 2Health News:Citalopram, a Boon in Treating Depressed Heart Patients 2Health News:New Cause of Chronic Liver Disease Identified in HIV-positive Patients 2Health News:New Cause of Chronic Liver Disease Identified in HIV-positive Patients 3
... advanced multi-functional microplate detection system, ,offers ... without compromising flexibility. ,The Ultra ... the Ultra instrument platform. New features ... to the flexibility of the existing ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
... High sensitivity and fast ... eight different radiometric and ... system with true high ... assays, by exploiting the ...
Medicine Products: